NCT03873064 Body Mass Index (BMI) and Quality of Life (QoL) in Cancer Patients
| NCT ID | NCT03873064 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Rome Tor Vergata |
| Condition | Neoplasm Malignant |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,380 participants |
| Start Date | 2019-01-15 |
| Primary Completion | 2029-01-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,380 participants in total. It began in 2019-01-15 with a primary completion date of 2029-01-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
BMI is a simple and widely recorded variable that may capture obesity or cachexia in cancer patients. How BMI is associated to health-related quality of life (HR-QoL) in such patients is poorly investigated. High BMI may be associated to obesity, an increased burden of comorbidity, reduced physical activity and, in some settings, to more aggressive oncological disease. On the other hand, low BMI may reflect enhanced weight loss, cachectic syndrome, higher tumor burden and adverse prognostic features which all deteriorate quality of life. The aim of the present study is to evaluate the association of BMI and HR-QoL as measured by the EORTC-QLQ-C30 questionnaire in several cancer settings (such as localized vs metastatic or distinct primary tumors).
Eligibility Criteria
Inclusion Criteria: 1. Histologically confirmed diagnosis of solid tumor 2. Age \>18 years 3. Signed informed consent 4. Life expectancy \> 12 weeks Exclusion Criteria: 1. Inability to fill out the EORTC QLQ-C30 questionnaire. 2. Absence of a certain diagnosis of solid tumor (e.g. subjects on screening programs) 3. Diagnosis of second malignancies that might bias results interpretation
Contact & Investigator
Mario Roselli
STUDY CHAIR
Tor Vergata University Hospital
Frequently Asked Questions
Who can join the NCT03873064 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Neoplasm Malignant. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03873064 currently recruiting?
Yes, NCT03873064 is actively recruiting participants. Contact the research team at v.formica1@gmail.com for enrollment information.
Where is the NCT03873064 trial being conducted?
This trial is being conducted at Rome, Italy.
Who is sponsoring the NCT03873064 clinical trial?
NCT03873064 is sponsored by University of Rome Tor Vergata. The principal investigator is Mario Roselli at Tor Vergata University Hospital. The trial plans to enroll 1,380 participants.